期刊
BIOORGANIC & MEDICINAL CHEMISTRY
卷 72, 期 -, 页码 -出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmc.2022.116913
关键词
Glioblastoma multiforme; Blood brain barrier; Temozolomide; Tumour-associated macrophages; T regulatory cells; Particle delivery; Immune checkpoint inhibitor; Cytokines and cell signalling; short interfering RNA (siRNA); Hyperthermal therapy
资金
- BBSRC [BB/T00875X/1]
- EPSRC [EP/R513209/1]
This review explores the combination of particle delivery systems and immunotherapy for the effective treatment of glioblastoma multiforme (GBM) over the past three years.
Glioblastoma Multiforme (GBM) is a multifaceted and complex disease, which has experienced no changes in treatment for nearly two decades and has a 5-year survival rate of only 5.4%. Alongside challenges in delivering chemotherapeutic agents across the blood brain barrier (BBB) to the tumour, the immune microenvironment is also heavily influenced by tumour signalling. Immunosuppression is a major aspect of GBM; however, evidence remains conflicted as to whether pro-inflammatory or anti-inflammatory therapies are the key to improving GBM treatment. To address both of these issues, particle delivery systems can be designed to overcome BBB transport while delivering a wide variety of immune-stimulatory molecules to investigate their effect on GBM. This review explores literature from the past 3 years that combines particle delivery systems alongside immunotherapy for the effective treatment of GBM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据